Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol)
暂无分享,去创建一个
Rachel Glass | William Hollingworth | Peter Vickerman | Hannah Fraser | David Whiteley | Matthew Hickman | Paul Flowers | Sema Mandal | Daniela De Angelis | Pantelis Samartsidis | Peter Donnan | Graham Foster | Chris Metcalfe | Jeremy Horwood | Anne Presanis | Samreen Ijaz | Ruth Simmons | Ross J. Harris | P. Donnan | A. Presanis | D. De Angelis | P. Flowers | P. Vickerman | C. Metcalfe | W. Hollingworth | H. Innes | S. Hutchinson | M. Hickman | J. Dillon | G. Foster | N. Martin | L. Elliott | M. Ramsay | Ross J Harris | David Whiteley | K. Sinka | A. Murray | R. Gunson | S. Ijaz | Athene Lane | Alex Murray | J. Horwood | S. Mandal | R. Simmons | Mary Ramsay | D. Goldberg | N. Palmateer | V. Hope | Andrew McAuley | Sharon J Hutchinson | A. Lane | P. Samartsidis | M. Harris | A. Radley | David Goldberg | A. McAuley | Zoe Ward | A. Yeung | H. Harris | Lawrie Elliott | D. Liddell | Vivian Hope | S. Migchelsen | Andrew Radley | John F Dillon | Ann Eriksen | David Liddell | Natasha Martin | Lewis J Z Beer | Kate Drysdale | Lesley Graham | Rory N Gunson | Emma Hamilton | Helen Harris | Magdalena Harris | Ross Harris | Ellen Heinsbroek | Sarah Karen Inglis | Hamish Innes | Jade Meadows | Stephanie Migchelsen | Gareth Myring | Norah E Palmateer | Katy Sinka | Gabriele Vojt | Zoe Ward | Alan Yeung | G. Vojt | Jade Meadows | S. Inglis | E. Heinsbroek | L. Graham | Hannah Fraser | R. Glass | A. Eriksen | Lewis Beer | Kate Drysdale | E. Hamilton | G. Myring | L. Beer | Norah E. Palmateer
[1] J. Parry,et al. Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots , 2011, Journal of viral hepatitis.
[2] C. Treloar,et al. 'Not just methadone Tracy': transformations in service-user identity following the introduction of hepatitis C treatment into Australian opiate substitution settings. , 2014, Addiction.
[3] M. Alavi,et al. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment. , 2015, Journal of hepatology.
[4] Aasld Idsa Hcv Guidance Panel. Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.
[5] T. Rhodes,et al. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors , 2013, Harm Reduction Journal.
[6] P. Hayes,et al. Excess morbidity in the hepatitis C-diagnosed population in Scotland, 1991–2006 , 2010, Epidemiology and Infection.
[7] P. Vickerman,et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.
[8] J. Pawlotsky,et al. EASL Recommendations on Treatment of Hepatitis C 2015. , 2015, Journal of hepatology.
[9] W. Edmunds,et al. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales , 2006, BMC infectious diseases.
[10] P. Vickerman,et al. Is increased hepatitis C virus case‐finding combined with current or 8‐week to 12‐week direct‐acting antiviral therapy cost‐effective in UK prisons? A prevention benefit analysis , 2016, Hepatology.
[11] J. Lazarus,et al. Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention , 2014, PloS one.
[12] C. Treloar,et al. The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics. , 2012, Social science & medicine.
[13] M. Kretzschmar,et al. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? , 2013, Addiction.
[14] S. Bird,et al. Hospitalisation for an alcohol-related cause among injecting drug users in Scotland: increased risk following diagnosis with hepatitis C infection. , 2011, The International journal on drug policy.
[15] D. De Angelis,et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment , 2010, BMJ : British Medical Journal.
[16] C. Treloar,et al. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals , 2010, Journal of viral hepatitis.
[17] D. D. Des Jarlais,et al. Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs , 2011 .
[18] C. Treloar,et al. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] P. Klapper,et al. Where are people being tested for anti‐HCV in England? Results from sentinel laboratory surveillance , 2008, Journal of Viral Hepatitis.
[20] P. Vickerman,et al. Cost‐effectiveness of hepatitis C virus antiviral treatment for injection drug user populations , 2012, Hepatology.
[21] J. Pawlotsky,et al. EASL recommendations on treatment of hepatitis C 2014. , 2014, Journal of hepatology.
[22] M. Hellard,et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals , 2013, Hepatology.
[23] H. Hagan,et al. Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. , 2016, The Cochrane database of systematic reviews.
[24] J. Parry,et al. Hepatitis C Infection Among Injecting Drug Users in England and Wales (1992–2006): There and Back Again? , 2009, American journal of epidemiology.
[25] H. Innes,et al. Liver mortality attributable to chronic hepatitis C virus infection in Denmark and Scotland—Using spontaneous resolvers as the benchmark comparator , 2016, Hepatology.
[26] S. Hutchinson,et al. Rapid Decline in HCV Incidence among People Who Inject Drugs Associated with National Scale-Up in Coverage of a Combination of Harm Reduction Interventions , 2014, PloS one.
[27] M. Jauffret-Roustide,et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. , 2018, Journal of hepatology.
[28] Jean-Michel Pawlotsky,et al. EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.
[29] Steven L. Scott,et al. Predicting the Present with Bayesian Structural Time Series , 2013, Int. J. Math. Model. Numer. Optimisation.
[30] Peter Vickerman,et al. Optimal Control of Hepatitis C Antiviral Treatment Programme Delivery for Prevention amongst a Population of Injecting Drug Users , 2011, PloS one.
[31] M. Dickie,et al. Global Health Sector Strategy on Viral Hepatitis : What does it mean for Canadians ? , 2018 .
[32] M. Dumont,et al. European Association for the Study of the Liver , 1971 .
[33] S. Bird,et al. Hepatitis C Virus Infection in Scotland: Epidemiological Review and Public Health Challenges , 2006, Scottish medical journal.
[34] S Reza-Paul,et al. Evaluating large-scale HIV prevention interventions: study design for an integrated mathematical modelling approach , 2007, Sexually Transmitted Infections.
[35] P. Hayes,et al. What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C? , 2015, Journal of hepatology.
[36] Peter Vickerman,et al. Assessment of the population-level effectiveness of the Avahan HIV-prevention programme in South India: a preplanned, causal-pathway-based modelling analysis. , 2013, The Lancet. Global health.
[37] P. Vickerman,et al. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. , 2012, Addiction.
[38] D. De Angelis,et al. New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England , 2016, Journal of viral hepatitis.
[39] S. Hutchinson,et al. Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them , 2006, Epidemiology and Infection.
[40] M. Harris. Managing expense and expectation in a treatment revolution: Problematizing prioritisation through an exploration of hepatitis C treatment 'benefit'. , 2017, The International journal on drug policy.
[41] G. Dore,et al. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention , 2015, Current opinion in HIV and AIDS.
[42] S. Fraser,et al. Harm reduction workers and the challenge of engaging couples who inject drugs in hepatitis C prevention. , 2016, Drug and alcohol dependence.
[43] M. Hellard,et al. Eradication of hepatitis C infection: The importance of targeting people who inject drugs , 2013, Hepatology.
[44] P. Vickerman,et al. How cost‐effective is hepatitis C virus treatment for people who inject drugs? , 2013, Journal of gastroenterology and hepatology.
[45] G. Dore,et al. Hepatitis C virus therapeutic development: in pursuit of "perfectovir". , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[46] Jennifer Jackson Bloom,et al. Recruiting and Retaining Mobile Young Injection Drug Users in a Longitudinal Study , 2010, Substance use & misuse.
[47] W. Irving,et al. Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection , 2014, Hepatology.
[48] P. Volberding,et al. Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals , 2016, BMC Public Health.
[49] S. Hutchinson,et al. Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland. , 2013, Journal of hepatology.
[50] Lu Gao,et al. Risk-factors for methadone-specific deaths in Scotland’s methadone-prescription clients between 2009 and 2013* , 2016, Drug and alcohol dependence.
[51] H. Innes,et al. Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. , 2013, The International journal on drug policy.
[52] Marion Bennie,et al. Data Resource Profile: The Scottish National Prescribing Information System (PIS) , 2016, International journal of epidemiology.
[53] R. Coutinho,et al. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users , 2007, Addiction.
[54] J. Ward,et al. Scaling‐up HCV prevention and treatment interventions in rural United States—model projections for tackling an increasing epidemic , 2018, Addiction.
[55] Steven L. Scott,et al. Predicting the Present with Bayesian Structural Time Series , 2013 .
[56] D. De Angelis,et al. Spatial mapping of hepatitis C prevalence in recent injecting drug users in contact with services , 2011, Epidemiology and Infection.
[57] J. Lambert,et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. , 2010, AIDS patient care and STDs.
[58] D. De Angelis,et al. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence , 2015, Current opinion in infectious diseases.
[59] Patricia B Wright,et al. The “Translators”: Engaging Former Drug Users as Key Research Staff to Design and Implement a Risk Reduction Program for Rural Cocaine Users , 2012, Substance use & misuse.
[60] J. Parry,et al. Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots , 2003, Journal of medical virology.
[61] T. Rhodes,et al. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. , 2010, Addiction.
[62] H. Innes,et al. Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland's experience. , 2015, The International journal on drug policy.
[63] H. Innes,et al. Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? , 2014, Gut.
[64] E. Rogers. Diffusion of preventive innovations. , 2002, Addictive behaviors.
[65] Jennifer A. Roberts,et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. , 2006, Health technology assessment.
[66] M. Hellard,et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[67] T. Rhodes,et al. Negotiating access to medical treatment and the making of patient citizenship: the case of hepatitis C treatment. , 2013, Sociology of health & illness.
[68] P. Hayes,et al. Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland , 2012, European journal of gastroenterology & hepatology.
[69] C. Fischbacher,et al. Understanding extreme mortality among prisoners: a national cohort study in Scotland using data linkage. , 2015, European journal of public health.
[70] M. Hellard,et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[71] P. Vickerman,et al. High response and re‐infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme , 2018, Journal of viral hepatitis.
[72] P. Vickerman,et al. P53 The cost-effectiveness of HCV antiviral treatment for injecting drug user populations , 2011, Gut.
[73] G. Dore,et al. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[74] G. Dore,et al. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study , 2014, Journal of viral hepatitis.
[75] W. Irving,et al. The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus‐infected people who inject drugs in England , 2019, Addiction.
[76] S. Michie,et al. Validation of the theoretical domains framework for use in behaviour change and implementation research , 2012, Implementation Science.
[77] W. Irving,et al. Sentinel laboratory surveillance of hepatitis C antibody testing in England: understanding the epidemiology of HCV infection , 2006, Epidemiology and Infection.
[78] A. Pharris,et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. , 2014, The International journal on drug policy.
[79] D. De Angelis,et al. An evidence synthesis approach to estimating Hepatitis C Prevalence in England and Wales , 2009, Statistical methods in medical research.
[80] J. Parry,et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. , 2011, Addiction.
[81] V. Braun,et al. Using thematic analysis in psychology , 2006 .
[82] S. Hutchinson,et al. Prevalence of hepatitis C among injectors in Scotland 1989–2000: declining trends among young injectors halt in the late 1990s , 2002, Epidemiology and Infection.
[83] P. Vickerman,et al. Impact of current and scaled‐up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings—what is required to achieve the WHO's HCV elimination targets? , 2018, Addiction.
[84] M. Harris. “Three in the Room” , 2015, Qualitative health research.
[85] V. Hope,et al. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004 , 2007, Journal of viral hepatitis.
[86] Deborah Watson-Jones,et al. HPTN 071 (PopART): Rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment – a study protocol for a cluster randomised trial , 2014, Trials.
[87] S. Hutchinson,et al. Detection of hepatitis C virus RNA in dried blood spots. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[88] Ross J. Harris,et al. Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. , 2012, European journal of public health.
[89] M. Buti,et al. Strategies to manage hepatitis C virus (HCV) disease burden , 2014, Journal of viral hepatitis.
[90] P. Hayes,et al. A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland , 2009, Statistical methods in medical research.
[91] H. Innes,et al. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause‐specific outcomes , 2015, Hepatology.
[92] S. Fraser,et al. Understanding decisions made about hepatitis C treatment by couples who inject drugs , 2016, Journal of viral hepatitis.
[93] M. Kretzschmar,et al. Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first? , 2015, Addiction.
[94] P. Vickerman,et al. Modelling the impact of a national scale‐up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland , 2018, Addiction.
[95] S. Bird,et al. A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland , 2008, British Journal of Cancer.
[96] M. Bellis,et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis , 2014, The Lancet.
[97] S. Bird,et al. Mortality of those who attended drug services in Scotland 1996–2006: Record-linkage study , 2012, The International journal on drug policy.
[98] M. Harris,et al. The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs? , 2015, The International journal on drug policy.
[99] A. Presanis,et al. Insights into the rise in HIV infections, 2001 to 2008: a Bayesian synthesis of prevalence evidence , 2010, AIDS.
[100] Peter Vickerman,et al. Positive impact of a large-scale HIV prevention programme among female sex workers and clients in South India , 2013, AIDS.
[101] M. Manns,et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. , 2012, JAMA.
[102] A. Gifford,et al. Resolute efforts to cure hepatitis C: Understanding patients’ reasons for completing antiviral treatment , 2015, Health.
[103] P. Whiting,et al. A systematic review of the effectiveness and cost-effectiveness of neuroimaging assessments used to visualise the seizure focus in people with refractory epilepsy being considered for surgery. , 2006, Health technology assessment.
[104] D. De Angelis,et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact , 2014, Journal of viral hepatitis.
[105] S. Bird,et al. Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996-99. , 2003, Addiction.
[106] T. Hallett,et al. Assessing evidence for behaviour change affecting the course of HIV epidemics: a new mathematical modelling approach and application to data from Zimbabwe. , 2009, Epidemics.
[107] P. Linsley,et al. Prison officers’ views about hepatitis C testing and treatment: a qualitative enquiry , 2017, Journal of clinical nursing.
[108] P. Hayes,et al. Excess liver‐related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care , 2011, Hepatology.
[109] T. Prevost,et al. Estimating the number of people with hepatitis C virus who have ever injected drugs and have yet to be diagnosed: an evidence synthesis approach for Scotland , 2015, Addiction.
[110] R. Chung,et al. Enhancing Our Understanding of Current Therapies for Hepatitis C Virus (HCV) , 2015, Current HIV/AIDS Reports.
[111] Steven L. Scott,et al. Inferring causal impact using Bayesian structural time-series models , 2015, 1506.00356.
[112] S. Hutchinson,et al. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross‐sectional survey data , 2014, Journal of viral hepatitis.
[113] S. Hutchinson,et al. Rise in testing and diagnosis associated with Scotland's Action Plan on Hepatitis C and introduction of dried blood spot testing , 2014, Journal of Epidemiology & Community Health.
[114] J. Arnsten,et al. "Hepatitis C treatment turned me around:" Psychological and behavioral transformation related to hepatitis C treatment. , 2015, Drug and alcohol dependence.
[115] P. Bruggmann. Treatment as prevention: The breaking of taboos is required in the fight against hepatitis C among people who inject drugs , 2013, Hepatology.
[116] C. Fischbacher,et al. Impact of opioid substitution therapy for Scotland's prisoners on drug‐related deaths soon after prisoner release , 2015, Addiction.
[117] R. Schinazi,et al. Treatment as prevention and cure towards global eradication of hepatitis C virus. , 2013, Trends in microbiology.
[118] P. Vickerman,et al. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons , 2013, BMJ Open.
[119] O. Weiland,et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[120] M. Pedrosa,et al. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV) , 2015, Advances in Therapy.